Диссертация (1139937), страница 12
Текст из файла (страница 12)
Thromb Res [Internet]. Elsevier Ltd; 2015; Available from:http://dx.doi.org/10.1016/j.thromres.2015.04.01610523. Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, et al.Meta-analysis: effect of patient self-testing and self-management of long-termanticoagulation on major clinical outcomes. Ann Intern Med [Internet]. 2011Apr 5 [cited 2015 Jun 15];154(7):472–82. Available from:http://www.ncbi.nlm.nih.gov/pubmed/2146434924.
Böhm M, Ezekovitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, ReillyPA, Schumaher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, DienerH-C, Hijazi Z, Wallentin L. Changes in renal function in patients with atrialfibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65:2481-2493.25. Brigden ML, Kay C, Le A et al. Audit of the frequency and clinical response toexcessive oral anticoagulation in an outpatient population. Am J Hematol 1998;59: 22-27.26.
Brodsky, S. V et al. Warfarin-related nephropathy occurs in patients with andwithout chronic kidney disease and is associated with an increased mortalityrate. Kidney Int. 80, 181–189 (2011).27. Brouwer JLP, Stoevelaar H, Sucker C. The Clinical Impact of DifferentCoagulometers on Patient Outcomes. Adv Ther [Internet]. 2014;31(6):639–56.Available from: http://link.springer.com/10.1007/s12325-014-0124-x28.
Calkins, Hugh et al. “2012 HRS/EHRA/ECAS Expert Consensus Statement onCatheter and Surgical Ablation of Atrial Fibrillation: Recommendations forPatient Selection, Procedural Techniques, Patient Management and Follow-Up,Definitions, Endpoints, and Research Trial Design: A Re.” Heart rhythm : theofficial journal of the Heart Rhythm Society 9.4 (2012): 632–696.e21. Web. 31Mar. 2015.29.
Camm AG, Lip GYH, De Caterina R, et al. 2012 focused update of the ESCGuidelines for the management of atrial fibrillation. Eur Heart J 2012; 33:2719–47.10630. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al.Guidelines for the management of atrial fibrillation: the Task Force for theManagement of Atrial Fibrillation of the European Society of Cardiology(ESC). Eur Heart J [Internet]. 2010 Oct [cited 2014 Jul 10];31(19):2369–429.Available from: http://www.ncbi.nlm.nih.gov/pubmed/2080224731. Camm AJ. Atrial fibrillation and risk . Clin Cardiol 2012; 35, Suppl 1: 1-2.
doi:10.1002/clc.21961.32. Camm, A John, Gregory Y H Lip, et al. “2012 Focused Update of the ESCGuidelines for the Management of Atrial Fibrillation: An Update of the 2010ESC Guidelines for the Management of Atrial Fibrillation. Developed with theSpecial Contribution of the European Heart Rhythm Association.” Europeanheart journal 33.21 (2012): 2719–47. Web. 10 July 2014.33. Camm, A John, Paulus Kirchhof, et al. “Guidelines for the Management ofAtrial Fibrillation: The Task Force for the Management of Atrial Fibrillation ofthe European Society of Cardiology (ESC).” European heart journal 31.19(2010): 2369–429.
Web. 10 July 2014.34. Chatrou, M. L. L., Winckers, K., Hackeng, T. M., Reutelingsperger, C. P. &Schurgers, L. J. Vascular calcification: The price to pay for anticoagulationtherapy with vitamin K-antagonists. Blood Rev. 26, 155–166 (2012).35. Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E andMukherjee D. Rivaroxaban and risk of myocardial infarction: insights from ameta-analysis and trial sequential analysis of randomized clinical trials. CoronArtery Dis 2013; 24: 628-635.36. Connolly SJ, Ezekovitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,Poque J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, ZhuJ, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LYSteering Committee and Investigators. N Engl J Med 2009; 361: 1139-1151.10737. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P.Assessing the direct costs of treating nonvalvular atrial fibrillation in theUnited States.
Value Health [Internet]. Jan [cited 2015 Jun 22];9(5):348–56.Available from: http://www.ncbi.nlm.nih.gov/pubmed/1696155338. Diener H-C. The novel oral anticoagulants should be used as 1st choice forsecondary prevention in patients with atrial fibrillation. Thrombosis andhemostasis 2013; 110: 493-495.39.
Eikelboom JW, O'Donnell M, Yusuf S et al. Rationale and design ofAVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonisttreatment. Am Heart J 2010; 159: 348-353.40. ESC Guidelines. Guidelines for the management of atrial fibrillation. // Eur.Heart J. 2010. V. 31. P. 2369–2429.41.
Ferri, Fred F. Ferri’s Clinical Advisor 2015: 5 Books in 1. Elsevier HealthSciences, 2014. Web. 1 Apr. 2015.42. Fox KA et al. Prevention of stroke and systemic embolism with rivaroxabancompared with warfarin in patients with non-valvular atrial fibrillation andmoderate renal impairment. Eur Heart J 2011; 32: 2387-2394.43. Gage BF, Van Walraven C, Pearce L et al. Selecting patients with atrialfibrillation for anticoagulation. Stroke risk stratification in patients takingaspirin. Circulation 2004; 110: 2287-2292.44. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V.,Singer D.E. Prevalence of Diagnosed Atrial Fibrillation in Adults: NationalImplications for Rhythm Management and Stroke Prevention: theAnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study // J.Am.
Med. Assoc. 2001. V. 285. P. 2370–2375.10845. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xainhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitordabagatran etexilate in patients with hepatic impairment.
Clin Pharmacokinet2013; 52 (4): 243-54.46. Granger C.B., Alexander J.H., McMurray J.J.V., et al. Apixaban versus warfarinin patients with atrial fibrillation. N Engl J Med 2011;365:981-92.47. Granger CB, Alexander JH, McMurray JJ, et al., for the ARISTOTLECommittees and Investigators. Apixaban versus warfarin in patients with atrialfibrillation. N Engl J Med 2011; 365: 981–92.48. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapyto prevent stroke in patients who have nonvalvular atrial fibrillation // AnnIntern Med.— 2007.— Vol. 146.— P.
857–867.49. Heidbuchel H., Verhamme P., Alings M. et al. European Heart RhythmAssociation Practical Guide on the use of new oral anticoagulants in patientswith non-valvular atrial fibrillation // Europace. 2013. Vol. 15. № 5. P. 625–651.50. Heidinger KS, Bernardo A, Taborski U, Müller-Berghaus G. Clinical Outcomeof Self-Management of Oral Anticoagulation in Patients with Atrial Fibrillationor Deep Vein Thrombosis.
Thromb Res [Internet]. Elsevier; 2000 May 15[cited 2015 Jun 14];98(4):287–93. Available from:http://www.thrombosisresearch.com/article/S004938480000181X/fulltext51. J Donald Easton, Renato D Lopes, M Cecilia Bahit, et al. «Apixaban comparedwith warfarin in patients with atrial fibrillation and previous stroke or transientischaemic attack: a subgroup analysis of the ARISTOTLE trial» Lancet Neurol2012; 11: 503–1152. January, Craig T et al. “2014 AHA/ACC/HRS Guideline for the Managementof Patients With Atrial Fibrillation: A Report of the American College of109Cardiology/American Heart Association Task Force on Practice Guidelines andthe Heart Rhythm Society.” Circulation 130.23 (2014): e199–267. Web. 2 Dec.2014.53.
Jm G, Am W, Perera R, Bankhead C, Fitzmaurice D. Self-monitoring and selfmanagement of oral anticoagulation ( Review ). Cochrane Collab. 2012;(4).54. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation,Classification, and Stratification55. Kerr C., Boone J., Connolly S., Greene M., Klein G., Sheldon R., Talajic M.Follow-up of atrial fibrillation —the initial experience of the CanadianRegistry of Atrial Fibrillation // Eur.
Heart J. 1996. V. 17. Suppl. C. P. 48–51.56. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of educationand self-monitoring in the management of warfarin therapy in older patientswith unstable control of anticoagulation. Br J Haematol. 2004;126(4):557–64.57. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, et al.Effect of a simple two-step warfarin dosing algorithm on anticoagulant controlas measured by time in therapeutic range: A pilot study.
J Thromb Haemost.2010;8(1):101–6.58. Kirchhof P, Auricchio A., Bax J., Crijns H., Camm J., Diener H.-C., Goette A.,Hindricks G., Hohnloser S., Kappenberger L., Kuck K.-H., Lip G.Y.H., OlssonB., Meinertz T., Priori S., Ravens U., Steinbeck G., Svernhage E., Tijssen J.,Vincent A. Breithardt G. Outcome parameters for trials in atrial fibrillation:executive summary. Recommendations from a consensus conference organizedby the German Atrial Fibrillation Competence NETwork (AFNET) and theEuropean Heart Rhythm Association (EHRA) // Eur. Heart J.
2007. V. 28. P.2803–2817.11059. Kubitza D, Becka M, Mueck W et al. The effect of extreme age, and gender, onthe pharmacology and tolerability of rivaroxaban— an oral direct Factor Xa inhibitor. Blood 2006;108: 905.60. Kubitza D, Becka M, Voith B et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.ClinPharmacolTher 2005; 78: 412-21.61. Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH,Damaraju CV, Schein JR, Lefebvre P. Real world comparative effectivenessand safety of rivaroxaban and warfarin in nonvalvular atrial fibrillationpatients.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
